|

T-DXd Clinical Trials

5 actively recruiting trials across 3 locations

Also known as: DS-8201a, DS-8201a, Trastuzumab deruxtecan, DS8201a, ENHERTU, Pertuzumab +1 more

Pipeline

Phase 1: 2Phase 2: 1Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Daiichi Sankyo2
  • SOLTI Breast Cancer Research Group1
  • Fudan University1
  • AstraZeneca1

Indications

  • Cancer5
  • Breast Cancer2
  • Locally Advanced or Metastatic Non-small Cell Lung Cancer1
  • Advanced Cancer1
  • Breast Cancer Stage IV1

Other2 trials

Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases
Phase 1/2
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
Phase 2

Duarte, California1 trial

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Research Site

Phase 1

Irvine, California1 trial

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

City of Hope At Orange County Lennar Foundation Cancer Center

Phase 1

Miami, Florida1 trial

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Miami Cancer Institute

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.